Introduction
The overall purpose of these guidelines is to provide guidance on best clinical practice in the treatment and management of adults with HIV infection and malignancy. The scope includes the management of diagnosed malignancies in people living with HIV but does not address screening for malignancies in this population. This is covered elsewhere in other BHIVA guidance where evidence is available to support it [1].
The guidelines are aimed at clinical professionals directly involved with, and responsible for, the care of adults with HIV infection, and at community advocates responsible for promoting the best interests and care of HIV-positive adults. They should be read in conjunction with other published BHIVA guidelines.
Downloads
British HIV Association guidelines for HIV-associated malignancies 2014
Appendices for these guidelines
Download Appendix 1
Consultation Comments
Download the comments received by the BHIVA Secretariat during the web consultation process
Presentation
Presentation on these guidelines is available to download and use to facilitate dissemination and implementation of the BHIVA guidance.
Download the PDF
Download the Powerpoint Presentation
Non-technical summary
Please note: The non-technical summary is less detailed than the full guideline and if you are reading this because it is relevant to your own healthcare, please do discuss any concerns or questions with your healthcare professionals.
Writing Group
Prof Mark Bower (Chair), Dr A Palfreeman (Vice Chair), Dr Maryam Alfa-Wali, Prof Chris Bunker, Dr Fiona Burns, Dr Duncan Churchill, Mr Simon Collins, Dr Kate Cwynarski, Dr Simon Edwards, Dr Paul Fields, Dr Kate Fife, Dr Eve Gallop-Evans, Dr Shireen Kassam, Dr Ranjababu Kulasegaram, Prof Charles Lacey, Dr Robert Marcus, Dr Sylvia Montoto, Dr Mark Nelson, Dr Tom Newsom-Davis, Dr Chloe Orkin, Ms Kate Shaw, Dr Melinda Tenant-Flowers, Dr Andrew Webb, Dr Sarah Westwell, Mr Matt Williams
Guidelines updates and date of next review
The guidelines will be next fully updated and revised in 2018. However, the Writing Group will continue to meet regularly to consider new information from high-quality studies and publish amendments and addendums to the current recommendations before the full revision date where this is thought to be clinically important to ensure continued best clinical practice.
Reference
HIV Medicine (2014), 15 (Suppl. 2), 1–92.